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ABSTRACT
Viperin is an IFN-stimulated gene (ISG)-encoded protein that was identified in human 
primary macrophages treated with IFN-γ and in human primary fibroblasts infected with 
cytomegalovirus (CMV). This protein plays multiple roles in various cell types. It inhibits 
viral replication, mediates signaling pathways, and regulates cellular metabolism. Recent 
studies have shown that viperin inhibits IFN expression in macrophages, while it enhances 
TLR7 and TLR9-mediated IFN production in plasmacytoid dendritic cells, suggesting that 
viperin can play different roles in activation of the same pathway in different cell types. 
Viperin also controls induction of ISGs in macrophages. However, the effect of viperin on 
induction of ISGs in cell types other than macrophages is unknown. Here, we show that 
viperin differentially induces ISGs in 2 distinct cell types, macrophages and fibroblasts 
isolated from wild type and viperin knockout mice. Unlike in bone marrow-derived 
macrophages (BMDMs), viperin downregulates the expression levels of ISGs such as bone 
marrow stromal cell antigen-2, Isg15, Isg54, myxovirus resistance dynamin like GTPase 2, 
and guanylate binding protein 2 in murine embryonic fibroblasts (MEFs) treated with type I 
or II IFN. However, viperin upregulates expression of these ISGs in both BMDMs and MEFs 
stimulated with polyinosinic-polycytidylic acid or CpG DNA and infected with murine CMV. 
The efficiency of viral entry is inversely proportional to the expression levels of ISGs in both 
cell types. The data indicate that viperin differentially regulates induction of ISGs in a cell 
type-dependent manner, which might provide different innate immune responses in distinct 
cell types against infections.
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INTRODUCTION
The IFN response is the first line of host defense against diverse pathogens. Pattern-
recognition receptors such as TLRs and RIG-I-like receptors recognize infectious agents and 
activate transcription factors, IFN-regulatory factors (IRFs) and NF-κB (1). The transcription 
factors subsequently mediate production of IFNs and pro-inflammatory cytokines. The 
secreted IFNs trigger induction of a large number of IFN-stimulated genes (ISGs) including 
2′5′-oligoadenylate synthetase (Oas), ribonuclease L, IFN-inducible dsRNA-dependent protein 
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kinase (Pkr), myxovirus resistance dynamin like GTPase (Mx), and interferon-stimulated gene 
15 (Isg15) through the JAK- STAT signaling pathway (1,2). The protein products of these ISGs 
play important roles as antipathogenic effector molecules in innate immunity (1,3).
Macrophages are innate immune cells that have functions in phagocytosis, antigen 
presentation, and immunomodulation (4). They can be polarized into 2 different subsets, 
classically activated macrophages (M1) and alternatively activated macrophages (M2) (5). 
M1 macrophages produce pro-inflammatory cytokines and provide a host defense against 
pathogens (6,7). M2 macrophages secrete anti-inflammatory cytokines and have repairing 
function (6,7). It has been reported that IFN responses affect the inflammatory functions of 
macrophages (8,9). Some ISG products expressed in macrophages promote inflammation 
and others inhibit (10-14).
Fibroblasts are ubiquitous mesenchymal cells that play roles in wound healing, antigen 
presentation, and maintenance of homeostasis (15-17). They are also important for immune 
responses. Fibroblasts can initiate inflammation in the presence of invading pathogens. 
They produce many different cytokines including IFNs and modulate extracellular matrix 
components against infectious pathogens (15-17). The ISG products expressed in fibroblasts 
exert their diverse antipathogenic properties (18-20).
Viperin (virus inhibitory protein, endoplasmic reticulum-associated, interferon-inducible) 
was first identified in human primary macrophages stimulated with IFN-γ and in human 
fibroblasts infected with human cytomegalovirus (CMV) (21,22). It is also induced in a 
variety of cells by treatment of type I, II, and III IFNs, ds B-form DNA, the dsRNA analog 
polyinosinic-polycytidylic acid (poly[I:C]), or LPS and infection of a wide range of viruses 
(23). Viperin protein has multiple functions in various cell types including macrophages, 
fibroblasts, dendritic cells, adipocytes, and astrocytes (24-30). This protein exhibits antiviral 
activity against many viruses (25-28), mediates signaling pathways or T cell development 
(29,31), and modulates cellular metabolism (24,30,32). It also plays a pivotal role in activation 
of macrophages, dendritic cells, and T cells (31,33-35). Recent studies have shown that viperin 
is a positive regulator of TLR7- and TLR9-mediated production of type I IFNs in plasmacytoid 
dendritic cells (pDCs) (29), while this protein is a negative regulator of mitochondrial 
antiviral signaling protein (MAVS)-linked IFN-β induction in macrophages (36). It suggests 
that viperin differentially regulates IFN induction in different cell types. Viperin also 
upregulates expression of most ISGs in macrophages in the absence or presence of type I 
IFN (36). Despite the importance of ISG products in innate immunity, the effect of viperin on 
induction of ISGs in cell types other than macrophages has not been examined.
In this study, we show that viperin differentially regulates ISG induction in two distinct 
cell types, macrophages and fibroblasts treated with type I or II IFNs. Viperin upregulates 
ISG expression in bone marrow-derived macrophages (BMDMs) treated with IFNs, while it 
downregulates ISG expression in murine embryonic fibroblasts (MEFs). Interestingly, viperin 
upregulates ISG expression in both BMDMs and MEFs stimulated with poly(I:C), CpG DNA, 
or CMV other than IFNs. The efficiency of viral entry depends on the levels of ISG expression 
in both cell types treated with CMV in the absence or presence of IFNs. Our data indicate 
that viperin differentially regulates ISG induction in a cell type-dependent manner under 
IFNs treatments, and in a stimulus-dependent manner through an IFN signaling pathway. It 
suggests that viperin-mediated differential expression of ISGs might provide different innate 
immune responses in distinct cell types against diverse pathogens.
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MATERIALS AND METHODS
Cells, viruses, antibodies, and reagents
Murine bone marrow cells and MEFs used in the study were isolated from wild type (WT) 
or viperin (Rsad2) knockout (KO) C57BL/6 mice (24,34). MEFs were immortalized by serial 
passages as described previously (24).
The Smith strain of murine cytomegalovirus (MCMV) and monoclonal antibody Croma 101 
(anti-immediate early 1 [IE1]) were kindly provided by Dr. W.J. Britt (University of Alabama 
at Birmingham). Viperin was detected with the monoclonal mouse antibody to viperin (MaP.
VIP) described previously (21,27). The monoclonal mouse anti-ISG15 antibody (Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA), monoclonal rat anti-GRP94 antibody (Enzo Life 
Sciences, Inc., Farmingdale, NY, USA), and horseradish peroxidase-conjugated goat anti-
mouse or anti-rat IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, 
USA) were used. Universal type I IFN (PBL Assay Science, Piscataway, NJ, USA), recombinant 
mouse IFN-γ (R&D systems, Minneapolis, MN, USA), poly(I:C) (InvivoGen, San Diego, 
CA, USA), CpG DNA (Enzo Life Sciences, Inc.), and Lipofectamine 2000 (Thermo Fisher 
Scientific, Waltham, MA, USA) were also used.
Mouse M-CSF was stably expressed in CHO cells and the culture supernatants containing the 
secreted M-CSF were used for generation of BMDMs as described previously (37).
Generation of BMDMs
To generate BMDMs, the bone marrow cells from femurs and tibias of mice were harvested 
and plated in culture medium (RPMI [Hyclone Laboratories Inc., South Logan, UT, USA], 
10% FBS [Hyclone Laboratories Inc.], 1% penicillin/streptomycin [Sigma-Aldrich, St. Louis, 
MO, USA]) containing 10% M-CSF supernatants for 7 days. BMDMs cultured in M-CSF 
conditioned media were washed and re-plated in cell culture dishes (SPL Life Sciences, 
Pocheon, Korea) containing culture medium without M-CSF for 24 h.
Stimulation of BMDMs and MEFs
BMDMs and MEFs were treated with 1000 U/ml IFN-I (PBL Assay Science) or 100 ng/ml 
IFN-γ (R&D systems) for 24 h. The cells were transfected with 1 μg/ml poly(I:C) (InvivoGen) 
or 1 μg/ml CpG DNA (Enzo Life Sciences, Inc.) using Lipofectamine 2000 (Thermo Fisher 
Scientific). The cells were infected with MCMV at the initial multiplicity of infection (MOI) of 
0.2 or 2 in the absence or presence of IFNs, and incubated for 24 h.
Immunoblot analysis
Cells were harvested and lysed in lysis buffer (1% Triton X-100 in TRIS-buffered saline) 
containing proteinase inhibitors. Supernatants of lysates were collected, and the 
concentration of proteins was measured by bicinchoninic acid (BCA) assay (Thermo 
Fisher Scientific). The proteins were separated on 15% SDS-PAGE gels and transferred 
to polyvinylidene fluoride membranes (Millipore, Burlington, MA, USA). The blots were 
blocked with 5% skim milk and 0.05% Tween in PBS for 1 h, incubated with primary 
antibodies for 1 day, probed with horseradish peroxidase-conjugated secondary antibodies 
for 1 h, followed by incubation with enhanced chemiluminescence reagents (Thermo Fisher 
Scientific). The intensity of bands was analyzed using ImageJ software.
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Immunofluorescence
Cells were grown in 24-well cell culture plates containing a 13-mm-diameter coverslip. 
The coverslips were harvested by washing cells with PBS and then fixing cells with 3% 
paraformaldehyde in PBS for 45 min at room temperature. The coverslips were washed with 
PBS and permeabilized with 0.1% Triton X-100 and 0.01% SDS in PBS for 7 min. The coverslips 
were then blocked with 0.2% Tween in PBS containing 10% normal goat serum (Thermo Fisher 
Scientific) for 20 min at room temperature, followed by the addition of the monoclonal mouse 
antibody Croma 101 (anti-IE1), and incubated for 1 h at room temperature. The coverslips 
were washed with 0.2% Tween in PBS and incubated with anti-mouse Ig secondary antibody 
conjugated to dye (Thermo Fisher Scientific) for 45 min at room temperature. The coverslips 
were washed with 0.2% Tween in PBS, rinsed once in PBS, and mounted with ProLong Gold 
Antifade reagent (Molecular Probes, Eugene, OR, USA). The images were acquired with a 
Zeiss LSM700 scanning laser confocal microscope (Carl Zeiss AG, Oberkochen, Germany) and 
analyzed using Zeiss ZEN 2012 software and ImageJ software.
RNA extraction, cDNA preparation, and quantitative real-time PCR
Cells were collected and total RNA were extracted using RNeasy Mini kit (Qiagen, Hilden, 
Germany). The cDNA was synthesized with 1 μg RNA using Prime script RT reagent kit 
according to the manufacturer's instructions (Takara Bio, Kusatsu, Japan). The cDNA 
obtained from cells was quantified by quantitative real-time PCR (qRT-PCR) using TB 
Green Fast qPCR reagent kit (Takara Bio). The sequences of primers for the PCR are listed in 
Supplementary Table 1. The reaction included 95°C for 5 min, which was followed by a 3-step 
PCR program of 95°C for 30 s, 60°C for 5 s, and 72°C for 15 s repeated for 40 cycles. The PCR 
was performed in triplicate for each sample. The quantitation of the results was performed by 
the comparative Ct (2−ΔΔCt) method. The Ct value for each sample was normalized by the value 
for β-actin gene. Three independent experiments were analyzed statistically for differences in 
the mean values, and p values are indicated in the figures.
Statistical analysis
The data are presented as mean±SEM. Statistical significance was determined with unpaired 
2-tailed Student's t-test using GraphPad Prism 5 software. The p values less than 0.05 were 
considered significant.
RESULTS
Viperin differentially regulates expression of ISGs in 2 different cell types 
treated with IFNs
Viperin enhances ISG expression in macrophages in the absence or presence of type I IFN 
(36), but its effect on cell types other than macrophages has not been examined. We therefore 
investigated the role of viperin in ISG induction in 2 distinct cell types, macrophages and 
fibroblasts. Bone marrow cells were isolated from WT and viperin KO mice and differentiated 
into BMDMs in M-CSF conditioned media. MEFs were also isolated from these mice and 
immortalized as described previously (24). The expression levels of ISGs, Viperin, bone 
marrow stromal cell antigen-2 (Bst-2), Isg15, Isg54, myxovirus resistance dynamin like GTPase 
2 (Mx2), guanylate binding protein 2 (Gbp2), and Isg56 that are known to be highly increased 
in cells upon IFN stimulation (36,38-41), were measured in WT and viperin KO BMDMs or 
MEFs (Fig. 1). Consistent with previous studies (36), the increases in expression levels of these 
ISGs were greater in WT BMDMs compared with viperin KO BMDMs treated with type I IFN 
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Figure 1. Viperin differentially regulates ISG expression in BMDMs and MEFs treated with type I IFN. (A-D) The effect of viperin on expression of ISGs in BMDMs 
and MEFs upon type I IFN treatment. The bone marrow cells isolated from WT and viperin KO C57BL/6 mice were differentiated into BMDMs in M-CSF conditioned 
media for 7 days. The BMDMs were washed and plated in media without M-CSF for 24 h (A, B). MEFs were isolated from these mice and immortalized (C, D). The 
cells were treated with or without type I IFN (1,000 U/ml) for 24 h. The mRNA expression levels of ISGs in the cells were measured by qRT-PCR and normalized to 
β-actin mRNA (A, C). Data are presented as mean ± SEM of triplicate samples and are representative of three individual experiments. Expression of viperin and 
ISG15 proteins in the cells was detected by immunoblot using anti-viperin (MaP.VIP) or anti-ISG15 antibody (B, D). GRP94 served as a protein-loading control. 
Quantitation of ISG15 protein level was normalized to GRP94. 
*p<0.05; **p<0.01; ***p<0.001.
(Fig. 1A and Supplementary Fig. 1). The expression level of ISG15 protein in WT BMDMs was 
also higher than that of ISG15 in viperin KO BMDMs treated with type I IFN (Fig. 1B). Viperin was 
basally expressed in WT BMDMs and highly increased upon type I IFN stimulation (Fig. 1B) (34). 
In contrast, the increases in expression levels of these ISGs, except for Isg56, were less in WT MEFs 
compared with viperin KO MEFs treated with type I IFN (Fig. 1C and Supplementary Fig. 1). The 
expression level of ISG15 in WT MEFs was also lower than that of ISG15 in viperin KO MEFs treated 
with type I IFN (Fig. 1D). Viperin was not basally expressed in MEFs, but it was highly induced in 
WT MEFs treated with type I IFN (Fig. 1D). The results indicated that viperin affects the expression 
of ISGs in type I IFN-mediated signaling pathway and its effects are dependent on cell type.
Both type I and type II IFNs are cytokines that have potent antiviral inhibitory effects on 
innate immune response. Although they bind to different receptors, the type I IFN receptor 
(IFNAR1-IFNAR2 subunits) and the type II IFN receptor (IFNGR1-IFNGR2 subunits), they 
commonly activate the JAK/STAT pathway and induce expression of ISGs (42). To examine 
whether viperin affects type II IFN-mediated signaling pathway, the expression levels of 
ISGs were measured in WT and viperin KO BMDMs or MEFs upon IFN-γ stimulation (Fig. 2). 
Similar to the results from type I IFN treatment, viperin differently affects ISG expression in 
BMDMs and MEFs treated with IFN-γ (Fig. 2). The results suggested that viperin is a cell type-
specific regulator of ISG expression in type I or II IFN-mediated signaling pathway.
Viperin enhances expression of ISGs in cells treated with poly(I:C) or CpG DNA
Viperin can modulate production of IFN in various cells such as pDCs, T cells, and BMDMs 
(29,31,36). To investigate whether viperin regulates ISG expression in cells treated with certain 
stimuli which induce IFN production, the expression levels of ISGs, Viperin, Bst-2, Isg15, Isg54, 
Mx2, and Gbp2 were measured in WT and viperin KO BMDMs or MEFs transfected with poly(I:C) 
or CpG DNA (Fig. 3). The increases in expression levels of these ISGs were significantly greater 
in WT BMDMs compared with viperin KO BMDMs treated with poly(I:C) or CpG DNA (Fig. 3A). 
The expression level of ISG15 in WT BMDMs was also higher than that of ISG15 in viperin KO 
BMDMs treated with poly(I:C) or CpG DNA (Fig. 3B and C). Like in BMDMs, viperin enhances 
ISG expression in MEFs treated with poly(I:C) or CpG DNA (Fig. 3D-F). The results suggested 
that viperin plays a role as a positive regulator on expression of ISGs in response to certain 
stimuli which mediate IFN production.
Viperin differentially regulates expression of ISGs in different cell types upon 
viral infection and/or IFN treatment
To examine the effects of viperin on ISG expression in cells infected with virus, the 
expression levels of ISGs, Viperin, Bst-2, Oas1, Isg15, Isg54, Isg56, Mx2, and Gbp2 were measured 
in WT and viperin KO BMDMs or MEFs infected with MCMV in the absence or presence 
of type I IFN (Fig. 4). The increases in expression levels of these ISGs were greater in WT 
BMDMs compared with viperin KO BMDMs infected with MCMV both in the absence and 
presence of type I IFN (Fig. 4A). While the increases in expression levels of these ISGs were 
greater in WT MEFs compared with viperin KO MEFs infected with MCMV in the absence of 
type I IFN, those of these ISGs except for Isg56 were less in WT MEFs compared with viperin 
KO MEFs infected with MCMV in the presence of type I IFN (Fig. 4B). Similar results were 
obtained from BMDMs and MEFs infected with MCMV in the absence or presence of IFN-γ 
(Fig. 5A and B). The data indicated that like in CpG DNA treatment, viperin enhances ISG 
expression of both BMDMs and MEFs after DNA virus infection. However, the effects of 
viperin on ISG expression by viral infection in MEFs were overwhelmed by IFN treatment, 
resulting in that viperin differentially regulates ISG expression in these 2 cell types.
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Figure 2. Viperin differently induces ISG expression in BMDMs and MEFs treated with type II IFN. (A-D) The effect of viperin on expression of ISGs in BMDMs and 
MEFs upon type II IFN treatment. WT and viperin KO BMDMs (A, B) or MEFs (C, D) were treated with or without IFN-γ (100 ng/ml) for 24 h. The mRNA expression 
levels of ISGs in the cells were measured by qRT-PCR and normalized to β-actin mRNA (A, C). Data are presented as mean±SEM of triplicate samples and are 
representative of three individual experiments. Expression of viperin and ISG15 proteins in the cells was detected by immunoblot using anti-viperin (MaP.VIP) or 
anti-ISG15 antibody (B, D). GRP94 served as a protein-loading control. Quantitation of ISG15 protein level was normalized to GRP94. 
*p<0.05; **p<0.01; ***p<0.001.
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Figure 3. Viperin enhances ISG expression in both BMDMs and MEFs transfected with poly(I:C) or CpG DNA. (A-F) The effect of viperin on expression of ISGs 
in BMDMs and MEFs upon poly(I:C) or CpG DNA treatment. WT and viperin KO BMDMs (A-C) or MEFs (D-F) were treated with lipofectamine 2000 (Lipo), or 
transfected with poly(I:C) (1 μg/ml) or CpG DNA (1 μg/ml) for 24 h. The mRNA expression levels of ISGs in the cells were measured by qRT-PCR and normalized 
to β-actin mRNA (A, D). Data are presented as mean±SEM of triplicate samples and are representative of three individual experiments. Expression of viperin 
and ISG15 proteins in the cells was detected by immunoblot using anti-viperin (MaP.VIP) or anti-ISG15 antibody (B, C, E, F). GRP94 served as a protein-loading 
control. Quantitation of ISG15 protein level was normalized to GRP94. 
*p<0.05; **p<0.01; ***p<0.001.
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Figure 4. Viperin differentially regulates ISG expression in BMDMs and MEFs treated with MCMV and/or type I IFN. (A, B) The effect of viperin on expression of 
ISGs in BMDMs and MEFs infected with MCMV in the absence or presence of type I IFN. WT and viperin KO BMDMs (A) or MEFs (B) were treated with or without 
type I IFN (1,000 U/ml) for 8 h and then infected with MCMV at an MOI of 0.2 for 24 h. The mRNA expression levels of ISGs in the cells were measured by qRT-PCR 
and normalized to β-actin mRNA. Data are presented as mean ± SEM of triplicate samples and are representative of three individual experiments. 
*p<0.05; **p<0.01; ***p<0.001.
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Figure 5. Viperin differently induces ISG expression in BMDMs and MEFs treated with MCMV and/or type II IFN. (A, B) The effect of viperin on expression of ISGs 
in BMDMs and MEFs infected with MCMV in the absence or presence of type II IFN. WT and viperin KO BMDMs (A) or MEFs (B) were treated with or without IFN-γ 
(100 ng/ml) for 8 h and then infected with MCMV at an MOI of 0.2 for 24 h. The mRNA expression levels of ISGs in the cells were measured by qRT-PCR and 
normalized to β-actin mRNA. Data are presented as mean±SEM of triplicate samples and are representative of three individual experiments. 
*p<0.05; **p<0.01; ***p<0.001.
MCMV entry depends on viperin-mediated ISG expression
To determine whether viperin-mediated ISG expression affects viral infection, the efficiency 
of MCMV entry into WT and viperin KO BMDMs or MEFs were measured (Fig. 6). WT and 
viperin KO BMDMs were infected with MCMV for 24 h in the absence or presence of type I 
or II IFN (Fig. 6A and B). Cells expressing an MCMV protein, IE1 protein, were monitored 
(Fig. 6A). The efficiency of viral entry was quantitated by the percentage of cells expressing 
IE1 protein (Fig. 6B). The number of IE1-positive cells was less in WT BMDMs compared with 
viperin KO BMDMs infected with MCMV in the absence or presence of IFNs. Similar patterns 
of viral entry were also obtained from BMDMs infected with MCMV at low multiplicity of 
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Figure 6. MCMV entry is inversely proportional to viperin-mediated ISG expression. (A-D) The efficiency of MCMV entry into BMDMs and MEFs infected with MCMV 
in the absence or presence of IFNs. WT and viperin KO BMDMs (A, B) or MEFs (C, D) were treated with or without type I IFN (1,000 U/ml) or IFN-γ (100 ng/ml) for 
8 h and then infected with MCMV at an MOI of 2 for 24 h. The cells were stained with antibody specific to the MCMV protein IE1 (green) to identify infected cells. 
Nuclei were stained with DAPI (blue). A representative image from two individual experiments was shown (scale bar=100 μm) (A, C). The efficiency of MCMV 
entry into the cells was quantitated (B, D). The infected cells were counted in each image (n=10). The percentage of MCMV positive cells per total cells in each 
image was calculated. Data are presented as mean±SEM. 
*p<0.05; ***p<0.001.
infection (Supplementary Fig. 2). While the number of IE1-positive cells was less in WT 
MEFs compared with viperin KO MEFs infected with MCMV in the absence of IFNs, that was 
greater in WT MEFs compared with viperin KO MEFs infected with MCMV in the presence 
of IFNs (Fig. 6C and D). The results indicated that the efficiency of viral entry is inversely 
proportional to the expression levels of ISGs mediated by viperin in both cell types.
DISCUSSION
ISG products play critical roles in innate immunity against infectious pathogens (1,3). 
ISGs are induced by various stimuli including pathogens and IFNs. It suggested that ISG 
expression can be regulated by two distinct signaling pathways, the signaling pathways to 
induce IFN production and the JAK/STAT pathway to induce IFN-mediated ISG expression 
(1,3). Viperin is a highly induced ISG protein in many cell types including macrophages and 
fibroblasts (23). Our study showed that viperin differentially regulates ISG expression in 
BMDMs and MEFs in responses to IFNs. Viperin promoted the increases in ISG expression 
of BMDMs, while it diminished the increases in ISG expression of MEFs treated with IFNs. 
Some ISGs including viperin have cell type-specific property (11,43). Therefore, our data 
indicated that viperin modulates ISG expression in a cell type-dependent manner in response 
to excessive IFN treatment. Previous studies have shown that viperin interacts with IL-1 
receptor associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6) at lipid 
droplet in pDCs, and MAVS at mitochondria in BMDMs to regulate the signaling pathway 
for IFN production (29,36). However, viperin interactions to modulate the JAK/STAT 
pathway for ISG induction under IFN treatment are unknown. The possible interactions 
between viperin and the signaling pathway components such as JAK protein kinases, STAT 
proteins, and STAT-IRF complexes may affect viperin-mediated and cell type-dependent ISG 
expression. Recently, it has been reported that both type I IFN and IFN-γ cause promoter 
binding of STAT1-STAT2-IRF9 complexes, a complete IFN-stimulated gene factor 3 (ISGF3) 
complex of the JAK-STAT pathway and highly induce expression of ISGs, while STAT2-IRF9 
complexes control basal expression of ISGs in the steady state (44). It suggested that viperin 
may interact with the ISGF3 complex at different efficiency in BMDMs and MEFs treated with 
IFNs, resulting in different phenotypes of innate immune responses in these cell types. STAT 
proteins regulate the interplay between transcriptional activators, such as Src homology 2 
domain and p300/CBP and the transcriptional activators contribute to selective expression of 
ISGs (45). It suggested that possible interactions of viperin and STAT proteins may determine 
expression of a set of ISGs in different cell types. The mechanism of viperin-mediated and 
cell type-dependent ISG expression needs to be further elucidated.
Our study also showed that viperin augments the increases in ISG expression of both BMDMs 
and MEFs treated with poly(I:C) or CpG DNA and infected with MCMV. However, viperin 
differently regulates production of type I IFN in different cell types (29,36). Upon TLR7- and 
TLR9 stimulation, viperin enhances K63-linked ubiquitination of IRAK1 by TRAF6, activates 
IRF7, and leads to production of type I IFN in pDCs (29). Upon poly(I:C) stimulation, viperin 
interacts with MAVS and restricts IRF3-dependent production of IFN-β in BMDMs (36). 
Therefore, our data indicated that viperin differentially regulates two distinct signaling 
pathways for IFN production and IFN-mediated ISG expression.
In addition, we have previously shown that viperin decreases expression of M1 macrophage 
cytokines including Tnf-a, Il-1b, and Il-6 in BMDMs treated with IFN-γ and LPS (34), while it 
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increases expression of ISGs in BMDMs treated with IFN-γ. IL-1β limits production of type I 
IFN through direct transcriptional downregulation and prostaglandin-endoperoxide synthase 
2-dependent prostaglandin E2 production. Inversely, type I IFN modulates the inflammatory 
microenvironment and suppresses production of cytokines (8,9,46). The balance of immune 
responses is important to prevent tissue damage and autoimmunity (9,46). Therefore, our 
data suggested that viperin may be involved in maintenance of a balance between ISGs and 
cytokines in inflammatory responses of macrophages.
The efficiency of MCMV entry was dependent on viperin-mediated ISG expression levels in 
cells infected with MCMV in the absence or presence of IFNs. The viral entry was less in both 
WT BMDMs and MEFs compared with viperin KO cells after MCMV infection. However, in 
the presence of IFNs, unlike in BMDMs, the viral entry was greater in WT MEFs compared 
with viperin KO MEFs after MCMV infection. Our data indicated that the efficiency of viral 
entry is inversely proportional to the expression levels of ISGs shown in both cell types. Our 
data also suggested that although viperin increases viral replication by modulating cellular 
metabolism in the late stage of human cytomegalovirus infection (24,32), the expression levels 
of ISGs mediated by viperin may determine viral infectivity in the early stage of CMV infection. 
Alternatively, the efficiency of MCMV entry in cells infected with MCMV in the presence of IFNs 
may be affected by viperin itself. Upon a combined treatment of CMV and IFN, viperin is highly 
induced and its antiviral or proviral activity may differently acts on BMDMs and MEFs.
In conclusion, we demonstrated that viperin differentially regulates expression of ISGs 
in distinct cell types. The data suggested that viperin is a key regulator in production of 
inflammatory molecules such as IFNs, ISGs, and cytokines in innate immune responses, and its 
regulation mechanism is dependent on cell type or stimulus. Our findings may provide a clue to 
develop new strategies of IFN therapy in immune-mediated or infection-associated diseases.
ACKNOWLEDGEMENTS
This study was supported by grants from the National Research Foundation of Korea (NRF) 
funded by the Ministry of Science, ICT & Future Planning (NRF-2019R1H1A2079735 and 
2013M3A9D5072550) and a faculty research grant from Yonsei University College of Medicine 
for 2018 (6-2018-0168) to J.-Y. Seo, and the Brain Korea 21 PLUS Project for Medical Science, 
Yonsei University.
SUPPLEMENTARY MATERIALS
Supplementary Table 1
Primer sequences used for qRT-PCR
Click here to view
Supplementary Figure 1
Viperin upregulates Isg56 expression in both BMDMs and MEFs treated with type I IFN. 
(A, B) The effect of viperin on the expression of Isg56 in BMDMs and MEFs upon type I IFN 
treatment. WT and viperin KO BMDMs (A) or MEFs (B) were treated with or without type I 
IFN (1,000 U/ml) for 24 h. The mRNA expression levels of Isg56 in the cells were measured by 
13/16https://doi.org/10.4110/in.2019.19.e33
The Effects of Viperin on Induction of ISGs
https://immunenetwork.org
qRT-PCR and normalized to β-actin mRNA. Data are presented as mean±SEM of triplicate 
samples and are representative of three individual experiments.
*p<0.05; ***p<0.001.
Click here to view
Supplementary Figure 2
The efficiency of MCMV entry depends on viperin-mediated ISG expression. (A, B) The 
efficiency of MCMV entry into BMDMs infected with MCMV in the absence or presence of IFNs. 
WT and viperin KO BMDMs were treated with or without type I IFN (1,000 U/ml) or IFN-γ (100 
ng/ml) for 8 h and then infected with MCMV at an MOI of 0.2 for 24 h. The cells were stained 
with antibody specific to the MCMV protein IE1 (green) to identify infected cells. Nuclei were 
stained with DAPI (blue). A representative image from 2 individual experiments was shown 
(scale bar=100 μm) (A). The efficiency of MCMV entry into the cells was quantitated (B). The 
infected cells were counted in each image (n=10). The percentage of MCMV positive cells per 
total cells in each image was calculated. Data are presented as mean±SEM.
**p<0.01; ***p<0.001.
Click here to view
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